WFDC13 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the WFDC13 protein, a member of the whey acidic protein (WAP) domain family. WFDC13, like other WAP domain-containing proteins, is thought to play a significant role in regulating protease activity, particularly through its interaction with serine proteases. Serine proteases are enzymes that participate in a wide array of biological functions, including cellular signaling, immune response, and tissue maintenance. The WAP domain, a highly conserved feature of this protein family, is known for its inhibitory action on proteases, helping to control proteolysis and maintain a balanced proteolytic environment in various tissues. WFDC13 inhibitors act by modulating this regulatory capacity, affecting the processes governed by protease activity.
The mechanism of action for WFDC13 inhibitors involves binding to the WAP domain or other functional sites of the WFDC13 protein, thereby preventing its ability to interact with and inhibit specific target proteases. This inhibition alters the protease activity landscape, which can influence various biological processes, such as extracellular matrix remodeling, immune modulation, and cellular migration. WFDC13 inhibitors are valuable for researchers aiming to understand the precise role of WFDC13 in protease regulation and how its inhibition impacts cellular and molecular systems. By selectively blocking WFDC13, researchers can explore how this protein influences proteolytic control within tissues and contributes to broader biological pathways. These inhibitors serve as important tools for investigating the complex networks involved in protease regulation and their significance in maintaining cellular structure and function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, known to impact various cellular processes that might intersect with WFDC13's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor, which may alter cellular signaling pathways potentially affecting WFDC13. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor, potentially affecting the ERK/MAPK pathway, which could have indirect effects on WFDC13 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, which could modify signaling pathways relevant to WFDC13's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, potentially influencing signaling pathways indirectly related to WFDC13. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Inhibits V-ATPase, potentially impacting endosomal-lysosomal functioning, influencing WFDC13 indirectly. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Known to affect autophagy and lysosomal function, which might indirectly influence WFDC13. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
An autophagy inhibitor, which may indirectly impact WFDC13. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another potent PI3K inhibitor, potentially affecting WFDC13 activity through intracellular signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, possibly influencing cytoskeletal dynamics, potentially relevant to WFDC13's function. | ||||||